^abMcLeod RL, Aslanian R, del Prado M, Duffy R, Egan RW, Kreutner W, et al. (October 1998). "Sch 50971, an orally active histamine H3 receptor agonist, inhibits central neurogenic vascular inflammation and produces sedation in the guinea pig".The Journal of Pharmacology and Experimental Therapeutics.287 (1):43–50.doi:10.1016/S0022-3565(24)37761-4.PMID9765320.
^abc"SCH 50971".AdisInsight. 7 September 2001. Retrieved6 October 2025.
^abcdeHey JA, Aslanian R, Bolser DC, Chapman RW, Egan RW, Rizzo CA, et al. (September 1998). "Studies on the pharmacology of the novel histamine H3 receptor agonist Sch 50971".Arzneimittel-Forschung.48 (9):881–888.PMID9793613.
^abShih NY, Aslanian R, Lupo AT, Orlando S, Piwinski JJ, Green MJ, et al. (February 1998). "Trans-4-methyl-3-imidazoyl pyrrolidine as a potent, highly selective histamine H3 receptor agonist in vivo".Bioorganic & Medicinal Chemistry Letters.8 (3):243–248.doi:10.1016/s0960-894x(98)00020-1.PMID9871662.
^Yokota E, Kuyama S, Ogawa M, Kamei C (August 2008). "Substance P is involved in the effect of histamine H3 receptor agonist, Sch 50971 on nasal allergic symptoms in mice".International Immunopharmacology.8 (8):1083–1088.doi:10.1016/j.intimp.2008.03.018.PMID18550011.
^Yokota E, Kuyama S, Sugimoto Y, Ogawa M, Kamei C (October 2008). "Participation of histamine H3 receptors in experimental allergic rhinitis of mice".Journal of Pharmacological Sciences.108 (2):206–211.doi:10.1254/jphs.08164fp.PMID18845911.
^Leurs R, Vollinga RC, Timmerman H (1995). "The medicinal chemistry and therapeutic potentials of ligands of the histamine H3 receptor".Progress in Drug Research / Fortschritte der Arzneimittelforschung / Progrès des Recherches Pharmaceutiques. Vol. 45. pp. 107–165.doi:10.1007/978-3-0348-7164-8_4.ISBN978-3-0348-7166-2.PMID8545536.
